Atricure, Inc.
ATRC
Surgical & Medical Instruments & Apparatus
Mkt Cap
$1.059BPE
-28.45Debt
$61.87MCash
$64.97MEV
$1.056BFCF
-$24.72MP/E Ratio
-28.45Debt
$61.87MCash
$64.97MEV
$1.056BFCF
-$24.72MCharts data: {"Earnings":[{"time":"2014-12-30","value":-16211000},{"time":"2015-12-30","value":-27212000},{"time":"2016-12-30","value":-33338000},{"time":"2017-12-30","value":-26892000},{"time":"2018-12-30","value":-21137000},{"time":"2019-12-30","value":-35194000},{"time":"2020-12-30","value":-48155000},{"time":"2021-12-30","value":50199000},{"time":"2022-12-30","value":-46466000},{"time":"2023-12-30","value":-30438000}],"Sales":[{"time":"2014-12-30","value":107454000},{"time":"2015-12-30","value":129755000},{"time":"2016-12-30","value":155109000},{"time":"2017-12-30","value":174716000},{"time":"2018-12-30","value":201630000},{"time":"2019-12-30","value":230807000},{"time":"2020-12-30","value":206531000},{"time":"2021-12-30","value":274329000},{"time":"2022-12-30","value":330379000},{"time":"2023-12-30","value":399245000}],"Net Margins":[{"time":"2014-12-30","value":-0.15086455599605414},{"time":"2015-12-30","value":-0.20971831528650148},{"time":"2016-12-30","value":-0.2149327247290615},{"time":"2017-12-30","value":-0.15391835893678885},{"time":"2018-12-30","value":-0.10483063036254525},{"time":"2019-12-30","value":-0.152482377050956},{"time":"2020-12-30","value":-0.23316112351172463},{"time":"2021-12-30","value":0.1829883096573822},{"time":"2022-12-30","value":-0.1406445324914719},{"time":"2023-12-30","value":-0.07623890092549687}],"Assets":[{"time":"2014-12-30","value":158404000},{"time":"2015-12-30","value":273092000},{"time":"2016-12-30","value":276421000},{"time":"2017-12-30","value":267704000},{"time":"2018-12-30","value":356759000},{"time":"2019-12-30","value":557880000},{"time":"2020-12-30","value":714539000},{"time":"2021-12-30","value":615312000},{"time":"2022-12-30","value":585448000},{"time":"2023-12-30","value":613932000}],"Stockholders Equity":[{"time":"2014-12-30","value":132538000},{"time":"2015-12-30","value":186685000},{"time":"2016-12-30","value":168442000},{"time":"2017-12-30","value":161166000},{"time":"2018-12-30","value":249381000},{"time":"2019-12-30","value":247343000},{"time":"2020-12-30","value":412394000},{"time":"2021-12-30","value":483756000},{"time":"2022-12-30","value":456754000},{"time":"2023-12-30","value":466168000}],"ROE":[{"time":"2014-12-30","value":-0.12231209162655239},{"time":"2015-12-30","value":-0.1457642552963548},{"time":"2016-12-30","value":-0.19791975873000794},{"time":"2017-12-30","value":-0.16685901492870706},{"time":"2018-12-30","value":-0.08475786046250516},{"time":"2019-12-30","value":-0.14228823940843283},{"time":"2020-12-30","value":-0.11676940013676242},{"time":"2021-12-30","value":0.10376925557512465},{"time":"2022-12-30","value":-0.10173090985519558},{"time":"2023-12-30","value":-0.06529405707813492}],"ROA":[{"time":"2014-12-30","value":-0.10020580288376556},{"time":"2015-12-30","value":-0.09784248531630366},{"time":"2016-12-30","value":-0.11264701307064225},{"time":"2017-12-30","value":-0.0933082807877357},{"time":"2018-12-30","value":-0.04800719813655717},{"time":"2019-12-30","value":-0.059371190937119095},{"time":"2020-12-30","value":-0.061904248753392045},{"time":"2021-12-30","value":0.08971871180799335},{"time":"2022-12-30","value":-0.07288264713518536},{"time":"2023-12-30","value":-0.043462468156082436}]}
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Sector
![GKOS Logo](data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' width='18' height='18'><defs><linearGradient id="a" x1="3.349" x2="21.904" y1="3.122" y2="24.434" gradientUnits="userSpaceOnUse"><stop stop-color="%231A1E21"/><stop offset="1" stop-color="%2306060A"/></linearGradient></defs><path fill="url(%23a)" d="M0 0h18v18H0z"/><text x='50%' y='52%' dominant-baseline='middle' text-anchor='middle' font-size='5' font-family='sans-serif' fill='gray'>GKOS</text></svg>){kind=small}
![GMED Logo](data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' width='18' height='18'><defs><linearGradient id="a" x1="3.349" x2="21.904" y1="3.122" y2="24.434" gradientUnits="userSpaceOnUse"><stop stop-color="%231A1E21"/><stop offset="1" stop-color="%2306060A"/></linearGradient></defs><path fill="url(%23a)" d="M0 0h18v18H0z"/><text x='50%' y='52%' dominant-baseline='middle' text-anchor='middle' font-size='5' font-family='sans-serif' fill='gray'>GMED</text></svg>){kind=small}
In the chart Earnings are multiplied by this value.
Earnings Growth 23%
Earnings Stability -30%
Competitiveness and MOAT
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
| Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | -21% | -21% | -15% | -10% | -15% | -23% | 18% | -14% | -7.6% | -9% |
| ROA | -9.8% | -11% | -9.3% | -4.8% | -5.9% | -6.2% | 9% | -7.3% | -4.3% | -5.4% |
| ROE | -15% | -20% | -17% | -8.5% | -14% | -12% | 10% | -10% | -6.5% | -8.2% |
What is the average Net Margin?
The average Net Margin over the past 5 years is -8.74%.
What is the trend of Net Margin?
The trend of Net Margin over the past 5 years is +1.7%.
What is the average Return on Assets (ROA)?
The average ROA over the past 5 years is -3.27%.
What is the trend of Return on Assets (ROA)?
The trend of ROA over the past 5 years is +0.38%.
What is the average Return on Equity (ROE)?
The average ROE over the past 5 years is -6.78%.
What is the trend of Return on Equity (ROE)?
The trend of ROE over the past 5 years is +1.26%.
Safety & Stabiliy
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
| Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt FCF | -0.02 | -1.78 | -2.48 | -5.51 | -2.14 | -2.65 | -2.55 | -1.68 | -8.40 | -2.50 |
| Debt Equity | 0.00 | 0.24 | 0.24 | 0.23 | 0.24 | 0.16 | 0.12 | 0.14 | 0.14 | 0.14 |
| MIN | ||||||||||
| Graham Stability | - | - | - | - | - | - | - | - | - | - |
What is the Debt/FCF?
The Debt/FCF trailing twelve month is -2.50.
What is the trend of Debt/FCF?
The trend of Debt/FCF over the past 5 years is -0.37.
What is the Graham’s Stability?
Graham’s Stability measure stands at -.
Growth
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
| Years | 12-2016 | 12-2018 | 12-2020 | 12-2022 | Trend |
|---|---|---|---|---|---|
| Revenue | 14% | 15% | 25% | 21% | 0.29% |
| Net Income | - | - | - | - | - |
| Stockholders Equity | 16% | 13% | 4.2% | 2.1% | -1.5% |
| FCF | - | - | - | - | - |
What is the 5 year Revenue CAGR?
The Revenue CAGR over the past 5 years is +14.64%.
What is the trend of Revenue growth?
The trend of Revenue growth rate over the past 5 years is +0.29%.
What is the 5 year Earnings CAGR?
The Earnings CAGR over the past 5 years is +7.57%.
What is the trend of Earnings growth?
The trend of Earnings growth rate over the past 5 years is -.
What is the 5 year Equity CAGR?
The Equity CAGR over the past 5 years is +13.33%.
What is the trend of Equity growth?
The trend of Equity growth rate over the past 5 years is -1.46%.
What is the 5 year FCF CAGR?
The FCF CAGR over the past 5 years is -6.26%.
What is the trend of FCF growth?
The trend of FCF growth rate over the past 5 years is -.